Moudře a pomalu - editorial

Jiří Vítovec

Vnitr Lek 2016, 62(1):5-6  

Toxická epidermální nekrolýza - editorial

Jana Hercogová

Vnitr Lek 2016, 62(1):7  

Lyellův syndrom - editorial

Vladimír Vašků

Vnitr Lek 2016, 62(1):8  

Significance of alanine aminotransferase screening in blood donors for risk reduction of hepatitis B and C transmission by haemotherapy

Katarína Kusendová, Peter Gavorník, Peter Sabaka, Klára Sviteková

Vnitr Lek 2016, 62(1):9-16  

Background:The goal of the retrospective observatory cross-sectional study was to evaluate the benefit of alanine aminotransferase screening of blood donors in prevention of hepatitis B and C transmission by haemotherapy in context of actual screening methods. Methods:Donations with elevated ALT more than the defined limit (ALT men 80 IU/l, women 64 IU/l, spectrophotometric UV test, KUADRO^TM, BPC BioSed Srt, Castelnuovo di Porto Roma, Italy) and/or reactivity any of the hepatitis screening parameters HBsAg, anti-HBc, anti-HCV (chemiluminescence method, ARCHITECT i2000^TM, Illinois, USA) were evaluated....

"3P (Patient-Pulse-Prognosis) in heart failure" survey: focus on heart rate

Juraj Dúbrava

Vnitr Lek 2016, 62(1):17-24  

Background:The data on heart rate in chronic heart failure in the real-world practice in Slovakia are not sufficiently known. The objective of the "3P (Patient-Pulse-Prognosis) in heart failure" survey was to collect epidemiological data with particular emphasis on heart rate control in sinus rhythm. Methods:The survey was performed by 162 cardiologists and internists. Outpatients or clinically stable hospitalized patients diagnosed with chronic heart failure were included in the survey. No exclusion criteria for patients enrollment were used. A total of 4738 patients were prospectively included. Results:93.6%...

Changes in the prognosis and treatment of Waldenström macroglobulinemia. Literature overview and own experience

Zdeněk Adam, Luděk Pour, Marta Krejčí, Sabina Ševčíková, Eva Pourová, Eva Ševčíková, Zdeněk Král, Jiří Mayer

Vnitr Lek 2016, 62(1):25-39  

Waldenström macroglobulinemia is defined by the presence of monoclonal immunoglobulin IgM type (M-IgM) and evidence of lymphoplasmacytic bone marrow infiltration. The disease has an indolent course, the treatment is only initiated when the disease has begun to damage its carrier. The following symptoms are regarded as proven indications for initiating therapy: B symptoms, symptomatic lymphadenopathy, splenomegaly, anemia with hemoglobin below 100 g / l or thrombocytopenia < 100 × 10⁹/l, caused by lymphoplasmacytic bone marrow infiltration. Frequent indications for initiating treatment include clinical evidence of hyperviscosity or cryoglobulinemia....

Gene mutations connected to Waldenstöm macroglobulinemia

Kateřina Kutálková, Lenka Sedlaříková, Zdeněk Adam, Sabina Ševčíková

Vnitr Lek 2016, 62(1):40-43  

Waldenstöm macroglobulinemia (WM) is a rare lymphoproliferative disorder, currently classified as a monoclonal gammopathy, with incidence rate of 3 per million. The disease is characterized by presence of clonal B lymphocytes in the bone marrow and by presence of monoclonal immunoglobulin IgM in serum. It is mostly an indolent disorder, with median overall survival 6 years. Molecular pathogenesis of WM remains unclear, but deletion of 6q and 13q, trisomy of chromosomes 4 and 8 seem to be typical. Mutations of MYD88^L265P and CXCR4^WHIM are very common for WM and affect growth and survival of malignant cells. This work...

The SPRINT Research. A Randomized Trial of Intensive versus Standard Blood-Pressure Control

Jiří Widimský

Vnitr Lek 2016, 62(1):44-47  

Background:The most appropriate targets for systolic blood pressure to reduce cardiovascular morbidity and mortality among persons without diabetes remain uncertain. Methods:We randomly assigned 9 361 persons with a systolic blood pressure of 130 mm Hg or higher and an increased cardiovascular risk, but without diabetes, to a systolic blood-pressure target of less than 120 mm Hg (intensive treatment) or a target of less than 140 mm Hg (standard treatment). The primary composite outcome was myocardial infarction, other acute coronary syndromes, stroke, heart failure, or death from cardiovascular causes. Results:At...

Rare diagnostics of infective endocarditis after kidney transplantation

Ivana Dedinská, Petra Skalová, Michal Mokáň, Katarína Martiaková, Denisa Osinová, Miroslav Pindura, Blažej Palkoci, Marián Vojtko, Janka Hubová, Denisa Kadlecová, Ivona Lendová, Radovan Zacharovský, Filip Pekar, Lucia Kaliská

Vnitr Lek 2016, 62(1):48-51  

Introduction:Infective endocarditis in a patient after kidney transplantation is a serious infective complication which increases the risk of loss of the graft and also the mortality of patients. The most important predisposing factor is the immunosuppressive therapy - mainly induction immunosuppression. Material and case description:250 patients underwent kidney transplantation throughout the period of 12 years in the Transplant Center Martin. This set of patients included 5 patients (2 %) after heart valve replacement. We present the case of a patient after kidney transplantation with development of endocarditis of the bioprosthesis...

A rare case of mobile atherosclerotic plaque with a high embolic potential in the femoral artery

Daniel Rob, David Ručka, Miroslav Chochola, Debora Karetová, Jan Hrubý, Eliška Kusová, Jean Claude Lubanda

Vnitr Lek 2016, 62(1):52-56  

Atherosclerosis is a diffuse disease which may lead to the development of unstable atherosclerotic plaque. Its rupture can result in acute ischemic event. The atherosclerotic plaques with a mobile component are typical presentations of such instability and patients with these plaques are at high risk of acute ischemic events. In the current literature, substantial data regarding the mobile atherosclerotic plaques in carotid arteries and thoracic aorta is published. However there are almost no data concerning the mobile plaques in the peripheral arteries of the lower limbs. We present a rare case of a patient with generalized atherosclerosis, in whom...

Dangerous cucumbers - Leyll's syndrome

Ján Csomor, Bohuš Bunganič, Sergey Zakharov, Igor Pafčuga, Pavel Sedloň, Petr Urbánek

Vnitr Lek 2016, 62(1):57-61  

Leyll's syndrome (syndrome of toxic epidermal necrolysis) is a rare disease, firstly described by Scottish doctor of medicine Allan Lyell in 1956. It is characterized by huge skin and mucosa necrolysis, which affects at least 30 % of body surface, and systemic symptoms. According to the frequency of the occurrence it is an extremely rare condition, with an incidence of 0.5-2 cases per million residents per year. Leyll's syndrome is considered as a toxoallergic reaction, triggered mostly by some medication and it is associated with a very high mortality rate (in the literature reported between 30 to 90 %). Adequate and timely local and systemic treatment...

Toxic epidermal necrolysis

Dina Odarčenková, Milan Kvapil

Vnitr Lek 2016, 62(1):62-69  

Toxic epidermal necrolysis is a rare, acute and life-threatening disorder manifested by extensive separation of the epidermis and mucosal surfaces. It is a serious adverse response to administered drugs, mostly antibiotics, anticonvulsants or NSAIDs. First described by Scottish dermatologist Alan Lyell in 1956, it is also known as Lyell's syndrome. Mortality of the disease is high, therefore its early diagnosis is crucial and immediate initiation of appropriate patient care necessary. It is a rare disease with a very low incidence and serious prognosis, which is a considerable hindrance to undertaking large randomized clinical studies. It is therefore...

Z odborné literatury

Vnitr Lek 2016, 62(1):77-80  

Poslední rozloučení s panem profesorem MUDr. Vratislavem Schreiberem, DrSc.

Jan Škrha

Vnitr Lek 2016, 62(1):76  

Korespondence ke článku

Vnitr Lek 2016, 62(1):70-74  

EASD Postgraduate Course of Clinical Diabetes and its Complications, Prague 2015

Jan Brož

Vnitr Lek 2016, 62(1):75